

Cover Story
NCI
By Matthew Bin Han Ong
The pace of innovation in oncology has made U.S. cancer researchers prime targets for foreign state-sponsored programs aimed at diverting intellectual property.
By Matthew Bin Han Ong
In Brief


Funding Opportunities
Clinical Roundup


Drugs & Targets


Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
- Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?” - CBER Director Vinay Prasad dared to “say no to drugs”
- Michael Bishop, Nobel-winning cancer researcher, dies at 90
- Letai: “From this point forward, it really is much more like business as usual at the NCI.”














